PMC:4310921 / 650-1167 JSONTXT

{"project":"NEUROSES","denotations":[{"id":"T41","span":{"begin":19,"end":30},"obj":"CHEBI_8871"},{"id":"T42","span":{"begin":286,"end":297},"obj":"CHEBI_8871"},{"id":"T50","span":{"begin":190,"end":198},"obj":"PATO_0001688"},{"id":"T53","span":{"begin":100,"end":109},"obj":"CHEBI_81580"},{"id":"T54","span":{"begin":335,"end":344},"obj":"CHEBI_81580"},{"id":"T55","span":{"begin":424,"end":433},"obj":"CHEBI_81580"},{"id":"T62","span":{"begin":174,"end":180},"obj":"PATO_0000461"},{"id":"T64","span":{"begin":213,"end":217},"obj":"CHEBI_30780"},{"id":"T65","span":{"begin":213,"end":217},"obj":"PATO_0000384"},{"id":"T66","span":{"begin":234,"end":240},"obj":"PATO_0000383"},{"id":"T67","span":{"begin":378,"end":381},"obj":"CHEBI_39025"},{"id":"T68","span":{"begin":382,"end":387},"obj":"PATO_0001470"},{"id":"T69","span":{"begin":382,"end":387},"obj":"PATO_0001038"},{"id":"T70","span":{"begin":406,"end":411},"obj":"CHEBI_24433"},{"id":"T71","span":{"begin":498,"end":505},"obj":"CHEBI_5931"},{"id":"T72","span":{"begin":506,"end":516},"obj":"PATO_0001046"},{"id":"T76","span":{"begin":498,"end":516},"obj":"PM4888"}],"text":"Results\nThe median risperidone dosage was 1.55 mg/day (SD 1.14 mg/day, range 0.25-4.00 mg/day). The prolactin level (33.65±16.71 ng/mL, range 5.8-68.3 ng/mL) was higher than normal, and was elevated (≥15 ng/mL in male, ≥23.3 ng/mL in female) in about 84% of the patients. The dosage of risperidone was positively correlated with serum prolactin level (r=0.767, p\u003c0.001). The TG/HDL ratio was higher in the group with higher prolactin levels (i.e., ≥30 ng/mL), and hence might be a useful marker of insulin resistance."}